NEXTCURE INC (NXTC) Fundamental Analysis & Valuation

NASDAQ:NXTC • US65343E2072

Current stock price

11.64 USD
+0.43 (+3.84%)
Last:

This NXTC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NXTC Profitability Analysis

1.1 Basic Checks

  • In the past year NXTC has reported negative net income.
  • NXTC had a negative operating cash flow in the past year.
  • NXTC had negative earnings in each of the past 5 years.
  • NXTC had a negative operating cash flow in each of the past 5 years.
NXTC Yearly Net Income VS EBIT VS OCF VS FCFNXTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M

1.2 Ratios

  • NXTC's Return On Assets of -111.28% is on the low side compared to the rest of the industry. NXTC is outperformed by 78.14% of its industry peers.
  • The Return On Equity of NXTC (-159.81%) is worse than 64.80% of its industry peers.
Industry RankSector Rank
ROA -111.28%
ROE -159.81%
ROIC N/A
ROA(3y)-52.94%
ROA(5y)-39.88%
ROE(3y)-61.66%
ROE(5y)-45.43%
ROIC(3y)N/A
ROIC(5y)N/A
NXTC Yearly ROA, ROE, ROICNXTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80

1.3 Margins

  • NXTC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NXTC Yearly Profit, Operating, Gross MarginsNXTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

6

2. NXTC Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, NXTC has more shares outstanding
  • Compared to 5 years ago, NXTC has more shares outstanding
  • NXTC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NXTC Yearly Shares OutstandingNXTC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M
NXTC Yearly Total Debt VS Total AssetsNXTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • NXTC has an Altman-Z score of -13.55. This is a bad value and indicates that NXTC is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -13.55, NXTC is doing worse than 78.92% of the companies in the same industry.
  • There is no outstanding debt for NXTC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.55
ROIC/WACCN/A
WACCN/A
NXTC Yearly LT Debt VS Equity VS FCFNXTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • NXTC has a Current Ratio of 4.14. This indicates that NXTC is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of NXTC (4.14) is comparable to the rest of the industry.
  • NXTC has a Quick Ratio of 4.14. This indicates that NXTC is financially healthy and has no problem in meeting its short term obligations.
  • NXTC has a Quick ratio (4.14) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.14
Quick Ratio 4.14
NXTC Yearly Current Assets VS Current LiabilitesNXTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

1

3. NXTC Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.82% over the past year.
EPS 1Y (TTM)15.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, NXTC will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.74% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.06%
EPS Next 2Y35.02%
EPS Next 3Y22.31%
EPS Next 5Y14.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NXTC Yearly Revenue VS EstimatesNXTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2028 2029 2030 10M 20M 30M 40M
NXTC Yearly EPS VS EstimatesNXTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -20 -40 -60

1

4. NXTC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NXTC. In the last year negative earnings were reported.
  • Also next year NXTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NXTC Price Earnings VS Forward Price EarningsNXTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXTC Per share dataNXTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NXTC's earnings are expected to grow with 22.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.02%
EPS Next 3Y22.31%

0

5. NXTC Dividend Analysis

5.1 Amount

  • No dividends for NXTC!.
Industry RankSector Rank
Dividend Yield 0%

NXTC Fundamentals: All Metrics, Ratios and Statistics

NEXTCURE INC

NASDAQ:NXTC (4/10/2026, 8:00:01 PM)

11.64

+0.43 (+3.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-05
Earnings (Next)04-29
Inst Owners49.08%
Inst Owner Change0%
Ins Owners1.15%
Ins Owner Change0%
Market Cap41.44M
Revenue(TTM)N/A
Net Income(TTM)-55.84M
Analysts84.44
Price Target18.02 (54.81%)
Short Float %1.87%
Short Ratio1.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)43.94%
Min EPS beat(2)20.75%
Max EPS beat(2)67.14%
EPS beat(4)3
Avg EPS beat(4)-11.89%
Min EPS beat(4)-139.84%
Max EPS beat(4)67.14%
EPS beat(8)3
Avg EPS beat(8)-19.64%
EPS beat(12)6
Avg EPS beat(12)-10.45%
EPS beat(16)8
Avg EPS beat(16)-7.6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)2.34%
EPS NQ rev (3m)2.34%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.19
P/tB 1.19
EV/EBITDA N/A
EPS(TTM)-20
EYN/A
EPS(NY)-8.39
Fwd EYN/A
FCF(TTM)-11.6
FCFYN/A
OCF(TTM)-11.46
OCFYN/A
SpS0
BVpS9.82
TBVpS9.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -111.28%
ROE -159.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.94%
ROA(5y)-39.88%
ROE(3y)-61.66%
ROE(5y)-45.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.54%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.14
Quick Ratio 4.14
Altman-Z -13.55
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)30.09%
Cap/Depr(5y)71.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.54%
EPS Next Y58.06%
EPS Next 2Y35.02%
EPS Next 3Y22.31%
EPS Next 5Y14.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.97%
OCF growth 3YN/A
OCF growth 5YN/A

NEXTCURE INC / NXTC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NEXTCURE INC (NXTC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NXTC.


What is the valuation status of NEXTCURE INC (NXTC) stock?

ChartMill assigns a valuation rating of 1 / 10 to NEXTCURE INC (NXTC). This can be considered as Overvalued.


Can you provide the profitability details for NEXTCURE INC?

NEXTCURE INC (NXTC) has a profitability rating of 0 / 10.


Can you provide the financial health for NXTC stock?

The financial health rating of NEXTCURE INC (NXTC) is 6 / 10.


What is the expected EPS growth for NEXTCURE INC (NXTC) stock?

The Earnings per Share (EPS) of NEXTCURE INC (NXTC) is expected to grow by 58.06% in the next year.